Amgen’s cancer drug Kyprolis twice effective than rival’s Velcade

March 2, 2015 7:19 AM

3 0

Biotech giant Amgen Inc. on Sunday said that a new clinical research has found its cancer drug Kyprolis more efficient in treating relapsed multiple myeloma than its major rival Velcade.

In a press release, the drug maker said that a latest study has established its cancer medication Kyprolis twice effective than Takeda Pharmaceutical Co. and Johnson & Johnson’s drug Velcade.

Also read: TD Ameritrade buying rival Scottrade for $4 billion

Read more

To category page